One of the key targets that ZEB2/LSD1 directly represses is the pro-apoptotic BCL2L11 (BIM) gene, and consequently confers a selective sensitivity of ETP-ALL to LSD1i in vivo. The gene discussed is ZEB2; the disease is acute lymphoblastic leukemia.